Sun Pharma, Lupin among 9 BSE Healthcare stocks that hit new 52-week highs on Thursday

The healthcare sector witnessed an impressive surge in the stock market as several prominent companies listed on the BSE Healthcare Index achieved new 52-week highs. Leading the charge were renowned names such as Dr Reddy's Laboratories, Sun Pharmaceutical Industries, and Torrent Pharmaceuticals, making significant strides in the dynamic market.

The data was sourced from BSE at 1.05 pm, and the updates from the real-time data could come with a lag. The below data also pertains only to the time at which it was taken.

1. Dr Reddy's Laboratories

Dr Reddy's Laboratories, a leading global pharmaceutical company, reached a remarkable 52-week high of Rs 5,613.85.

2. Sun Pharma
India's largest pharmaceutical company Sun Pharma witnessed an impressive surge, touching a 52-week high of Rs 1,149.10.

3. Torrent Pharma
Torrent Pharmaceuticals achieved a significant milestone with a 52-week high of Rs 2,004.55. The company is known for its strong presence in the cardiovascular, central nervous system, and gastro-intestinal segments.

4. Natco Pharma
Natco Pharma demonstrated positive momentum as its stock reached a 52-week high of Rs 830.

5. Aurobindo Pharma
Aurobindo Pharma soared to new heights with a 52-week high of Rs 834.6.

6. Glenmark Pharma
Glenmark Pharma showcased strong market movement, hitting a 52-week high of Rs 832.9.

7. Glenmark Life Sciences
Glenmark Life Sciences witnessed remarkable growth, touching a 52-week high of Rs 673.2. The company, a subsidiary of Glenmark Pharmaceuticals, focuses on the discovery and development of APIs (Active Pharmaceutical Ingredients).

8. Lupin
Lupin celebrated an upswing in its stock price, reaching a 52-week high of Rs 987.8.

9. Zydus Lifesciences
Zydus Lifesciences achieved a notable milestone with a 52-week high of Rs 654. The company is a subsidiary of Cadila Healthcare.

(Disclaimer: This is an AI-generated article. Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)